Balanites fruits (1 kg) were defatted by n-hexane and successively extracted by maceration in each of dichloromethane, ethyl acetate, methanol and water. Extracts were filtered and concentrated under vacuum at 50 °C giving extracts E, F, G and H, respectively. Similarly, the fruit was extracted with methanol, cold water, hot water and 70% ethanol to give extracts A, B, C and D, respectively. The dried methanol extract (3 gm) was defatted with n-hexane. a B S t r a c t the antidiabetic activities of different extracts and fractions of Balanites aegyptiaca were tested in cultured c2c12 skeletal muscle cells and 3t3-l1 adipocytes. an 18-h treatment with 200 µg/ml of the sugars fraction (A1) showed the highest activity as it increased basal glucose uptake by 52% in muscle cells; which is twice the activity of 100 nM insulin [insulin equivalent (ie) = 2.0 ± 0.07]. the dichloromethane (E) and ethyl acetate (F) successive extracts exerted 37 and 41% increase in the glucose uptake, respectively. only E and F accelerated the triglyceride accumulation in pre-adipocytes undergoing differentiation, comparably with 10 µM rosiglitazone [rosiglitazone equivalent (re) was 1.6 ± 0.3 and 0.7 ± 0.1, respectively). gas chromatography (gc) analysis of A1 revealed the presence of xylose, rhamnose, sorbitol, fructose, galactose and glucose. the active extracts E and F were standardized by high-performance liquid chromatography (HPlc) to contain 0.031 and 0.239% of rutin, 0.007 and 0.004% of isorhamnetin, respectively.
INTRODUCTION
Balanites aegyptiaca Del. (Zygophyllaceae) is used traditionally in African countries as an anthelmintic [1] and in the treatment of jaundice. [2] The fruits are used as an oral antihyperglycemic in Egyptian folk medicine [3] and herbalists in the Egyptian market sell the fruits as an antidiabetic agent. However, quality control of such herbal products remains a great challenge. The aqueous extract of the mesocarp of the Balanites fruits revealed significant antidiabetic activities in STZ-induced diabetic rats and mice [3, 4] and several saponins were isolated from the mesocarp. [3, [5] [6] [7] [8] Nevertheless, the target tissues and mechanisms of action of this herb are not yet well understood.
The aim of the present study was to assess the antihyperglycemic activities of different extracts and fractions of Balanites aegyptiaca fruits defining target tissues and the corresponding group of bioactive compounds through cell-based bioassays using C2C12 myotubes and 3T3-L1 adipocytes.
positive control during the assay. [12, 14, 15] Five separate experiments, each with three replicates, were performed.
Adipogenesis assay
3T3-L1 cells seeded in 12-well plates were treated with the test solutions or 0.1% DMSO vehicle in differentiation medium during the entire differentiation period as described before. [12, 14, 15] Rosiglitazone 10 µM (Alexis Biochemicals, San Diego, CA, USA), dissolved in DMSO, was used as a positive control. Three separate experiments, each with three replicates, were performed.
RESULTS AND DISCUSSION

HPLC finger-print chromatograms of active extracts
Successive extracts E and F were analyzed by HPLC to develop a fingerprint chromatogram for each. The extracts were injected against available flavonoid reference compounds (rutin, isorhamnetin, quercetin, scopoletin, caffeic acid and hyperoside). Rutin and isorhamnetin were identified and used for standardization of the extracts (Figure 1 ). The concentrations of rutin in Balanites aegyptiaca F and E extracts were found to be 0.239 and 0.031% and those of isorhamnetin were 0.004 and 0.007%, respectively.
GC analysis of the sugar fraction
A GC chromatogram was developed as a fingerprint for the most active sugar fraction A1 (Figure 2 ). The relative retention times for xylose, rhamnose, sorbitol, fructose, galactose, glucose and glucuronic acid were 7.30, 8.29, 9.66, 9.80, 10.76, 11.07 and 14.25 min, respectively. Xylose, rhamnose, sorbitol, fructose, galactose and glucose were detected in the sugar fraction with area percentages of 1.35, 26.37, 1.18, 1.51, 49.22 and 13.2%, respectively, with an unknown peak at retention time 8.18 min constituting 4.96% of the total areas. A previous analysis of the glycosyl part identified within balanites fruit revealed the presence of galactose, mannose, arabinose, xylose, rhamnose and glucuronic acid. [16] Cell-based bioassays for antidiabetic activity
The enhancement of glucose uptake in muscle cells and the acceleration of triglyceride accumulation in differentiating adipocytes (increased adipogenesis) were studied for the plant extracts and fractions. The four extracts of balanites (A, B, C and D) exhibited similar significant activities on differentiated C2C12 myotubes as shown by their activities relative to an optimal dose of insulin (100 nM; insulin equivalents, IE: values of 0.7 ± 0.03, 0.6 ± 0.02, 0.7 ± 0.02 and 0.8 ± 0.02, respectively) ( Figure 3 ). Extraction of the defatted fruits with solvents of increasing polarity resulted in an increase in activity to become about 1.5-fold that of and saponin-rich (A3) fractions, respectively. [9, 10] The dried extracts and fractions were dissolved in dimethyl sulfoxide (DMSO; 0.1% final concentration) for biological screening.
HPLC analysis of active extracts
An HPLC method was adapted for analysing Balanites aegyptiaca E and F extracts. An Agilent 1100 series HPLC was used, equipped with Agilent G1311A quaternary pump, a G1314A variable wavelength detector and a G1328A manual injector. Balanites aegyptiaca ethyl acetate and dichloromethane fractions were dissolved in methanol (17.24 and 22.34 mg/ml, respectively), filtered through PTFE 0.45 µM syringe filter (Macherey-Nagel, Germany) and injected into a Hypersil 100 RP-18, 5 µm, 250 × 4 mm column. The mobile phase used was acetonitrile (solvent A) and 1% acetic acid in water (solvent B). Gradient elution was carried out at a flow rate of 1.0 ml/min as follows: 0-20 min 30 to 75% A in B. Measurements were made with an injection volume of 20 µl and UV detection at 370 nm. Standard calibration curves were prepared using five concentrations of isorhamnetin (1, 2, 4, 8 and 10 µg/ml) and rutin (4, 8, 10, 16 and 20 µg/ml) in methanol. For each sample, three replicate assays were performed.
GC analysis of the sugar fraction
Fraction A1 (70 mg) was extracted with hot water and derivatised. [11] The derivatised sugar solution (1 ul) was injected onto a 3 m × 250 µm capillary column packed with 14% cyanopropyl phenyl methyl (HP-1701) heated isothermally at 150 °C for 2 min, then temperature programmed at 7 °C/min to 200 °C. GC apparatus HP6890 was used and injector/detector (FID) temperature was 270 °C with nitrogen carrier gas at 40 ml/min. Sugar standards (xylose, rhamnose, sorbitol, fructose, galactose, glucose and glucuronic acid) were similarly prepared and injected to identify the retention time of each.
Cell culture
C2C12 myoblasts and 3T3-L1 preadipocytes (ATCC, Manassas, VA, USA) were cultured as previously described in Dulbecco's modified Eagle's medium. [12] [13] [14] C2C12 cells were treated with 200 µg/mL of extracts and fractions. Concentrations of 50 or 100 µg/mL were used for treating the 3T3-L1 preadipocytes. Diosgenin 50 µM (Sigma-Aldrich, Germany) was used for treating both cell lines. These concentrations were based on the maximum non-toxic concentrations determined in the employed cell lines following 18-h treatment.
Glucose transport assay
Differentiated C2C12 cells grown in 12-well culture plates were treated with the test solutions, vehicle control (0.1% DMSO) and a positive control (400 µg/mL metformin) for 18 h. Insulin 100 nM was added to one well as a second A1 standardized to contain monosaccharides and possessing the highest activity among all tested extracts and fractions. Indeed, it increased basal glucose uptake in skeletal muscle cells twice as much as insulin (IE = 2.0 ± 0.07) (Figures 2  and 3) . Diosgenin 50 µM, the main aglycone of the saponins of Balanites, did not show any activity on the two cell lines under the experimental conditions (results are not shown). Kamel et al., (1991) [3] reported previously that oral administration of 80 mg/kg bw of the aqueous extract of the fruit mesocarp, as well as the polysaccharide fraction (precipitated by excess of alcohol) and the supernatant (saponin-rich), revealed significant antidiabetic activities in STZ-induced diabetic mice. In another study on STZdiabetic rats, it was suggested that the antihyperglycemic effect of balanites aqueous extract (1.5 g/kg bw) was mediated through insulinomimetic effect as well as inhibition of intestinal α-amylase activity. [4] The present studies bring forth novel data showing that the reported antihyperglycemic activity of B. aegyptiaca can also be attributed to significant insulin-like and partly glitazonelike activities in peripheral tissues. Increased muscle basal glucose uptake thus participates in the traditionally known, and in vivo proven, antidiabetic effect of the balanites fruits. Moreover, the sugar part (A1) and the phenolic content (E and F) contribute to a large extent to this activity. On the other hand, some of the balanites bioactive fractions (E and F) may act in a manner similar to the thiazolidinedione (e.g. rosiglitazone) family by increasing insulin sensitivity in the fat tissue. [19] Further investigations are in progress to isolate bioactive compounds from these active fractions, possessing a greater activity compared to insulin, which could hold a great promise for developing oral antihyperglycemic lead compounds.
insulin in successive extracts E and F (IEs of 1.5 ± 0.07 and 1.6 ± 0.04, respectively). Only these two extracts revealed a significant activity in increasing the triglyceride accumulation in differentiated 3T3-L1 adipocytes comparable to that caused by 10 µM rosiglitazone (RE = 1.6 ± 0.03 and 0.7 ± 0.1, respectively) ( Figure 4 ). Both extracts were standardized to their phenolic content (Figure 1) . Many studies have already demonstrated the antihyperglycemic activity of flavonoids using different experimental models. [14, 17, 18] Fractionation of extract A on Diaion HP-20 gave fraction The rate of accumulation of triglycerides in differentiating 3T3 pre-adipocytes treated for 6 days with 50 µg/mL of each of A, A1, C, D, G and H and 100 µg/mL of each of A2, A3, B, E and F, 0.1% DMSO (vehicle) or 10 µM rosiglitazone in differentiation medium. Results were normalized to vehicle control in differentiation minus vehicle control in proliferation medium, and expressed as Rosiglitazone Equivalent (RE). Dotted lines represent the RE of 10 µM rosiglitazone (1 ± 0.07) that corresponds to 648 ± 51% intracellular triglyceride content (expressed as % of vehicle). Mean ± SEM for n = 3 to 4. The symbols (*) and (**) indicate a significant difference (p ≤ 0.05 and p ≤ 0.0001, respectively) from vehicle control.
